178 related articles for article (PubMed ID: 34302463)
21. Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry.
Wei XX; Kwak L; Hamid A; He M; Sweeney C; Flanders SC; Harmon M; Choudhury AD
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):314-319. PubMed ID: 35145218
[TBL] [Abstract][Full Text] [Related]
22. Sipuleucel-T (APC8015) for prostate cancer.
So-Rosillo R; Small EJ
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1163-7. PubMed ID: 17020451
[TBL] [Abstract][Full Text] [Related]
23. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
Wei XX; Perry J; Chang E; Zhang L; Hiatt RA; Ryan CJ; Small EJ; Fong L
Clin Genitourin Cancer; 2018 Jun; 16(3):184-190.e2. PubMed ID: 29352713
[TBL] [Abstract][Full Text] [Related]
24. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Small EJ; Lance RS; Gardner TA; Karsh LI; Fong L; McCoy C; DeVries T; Sheikh NA; GuhaThakurta D; Chang N; Redfern CH; Shore ND
Clin Cancer Res; 2015 Sep; 21(17):3862-9. PubMed ID: 25925891
[TBL] [Abstract][Full Text] [Related]
25. Evaluating immune responses after sipuleucel-T therapy.
Strauss J; Madan RA; Figg WD
Cancer Biol Ther; 2015; 16(8):1119-21. PubMed ID: 26054644
[TBL] [Abstract][Full Text] [Related]
26. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
Mulders PF; De Santis M; Powles T; Fizazi K
Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563
[TBL] [Abstract][Full Text] [Related]
27. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
28. Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.
Simpson EL; Davis S; Thokala P; Breeze PR; Bryden P; Wong R
Pharmacoeconomics; 2015 Nov; 33(11):1187-94. PubMed ID: 26017401
[TBL] [Abstract][Full Text] [Related]
29. Cancer immunotherapy: sipuleucel-T and beyond.
Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
[TBL] [Abstract][Full Text] [Related]
30. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
Di Lorenzo G; Ferro M; Buonerba C
BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
[TBL] [Abstract][Full Text] [Related]
31. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.
Schellhammer PF; Chodak G; Whitmore JB; Sims R; Frohlich MW; Kantoff PW
Urology; 2013 Jun; 81(6):1297-302. PubMed ID: 23582482
[TBL] [Abstract][Full Text] [Related]
32. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.
Sonpavde G; Di Lorenzo G; Higano CS; Kantoff PW; Madan R; Shore ND
Eur Urol; 2012 Apr; 61(4):639-47. PubMed ID: 22036643
[TBL] [Abstract][Full Text] [Related]
33. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.
Sheikh NA; Petrylak D; Kantoff PW; Dela Rosa C; Stewart FP; Kuan LY; Whitmore JB; Trager JB; Poehlein CH; Frohlich MW; Urdal DL
Cancer Immunol Immunother; 2013 Jan; 62(1):137-47. PubMed ID: 22865266
[TBL] [Abstract][Full Text] [Related]
34. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
Quinn DI; Vaishampayan U; Higano CS; Lin DW; Shore ND; Beer TM
Expert Rev Anticancer Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24224900
[TBL] [Abstract][Full Text] [Related]
35. Sipuleucel-T for the treatment of advanced prostate cancer.
Frohlich MW
Semin Oncol; 2012 Jun; 39(3):245-52. PubMed ID: 22595047
[TBL] [Abstract][Full Text] [Related]
36. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.
Handy CE; Antonarakis ES
Future Oncol; 2018 Apr; 14(10):907-917. PubMed ID: 29260582
[TBL] [Abstract][Full Text] [Related]
37. Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T.
Dorff T; Hirasawa Y; Acoba J; Pagano I; Tamura D; Pal S; Zhang M; Waitz R; Dhal A; Haynes W; Shon J; Scholz M; Furuya H; Chan OTM; Huang J; Rosser C
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376554
[TBL] [Abstract][Full Text] [Related]
38. Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research.
Graff JN; Drake CG; Beer TM
Urology; 2013 Feb; 81(2):381-3. PubMed ID: 23374810
[TBL] [Abstract][Full Text] [Related]
39. Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T.
McNamara M; Berry W
Clin Genitourin Cancer; 2015 Oct; 13(5):e361-4. PubMed ID: 25735199
[No Abstract] [Full Text] [Related]
40. Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.
Small EJ; Higano CS; Kantoff PW; Whitmore JB; Frohlich MW; Petrylak DP
Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):259-64. PubMed ID: 24957547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
